This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Jeffrey A. Mattes, MD
Princeton, NJ

JAMA. 1997;278(24):2141.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—In the article by Dr McCann and colleagues,¹ the differences between fenfluramine and more standard psychostimulants, eg, dextroamphetamine, were not discussed in detail.

Some of the mechanisms that the authors suggest might explain the serious adverse events from fenfluramine might also apply to standard psychostimulants, but is there evidence that standard psychostimulants (such as those prescribed for attention-deficit/hyperactivity disorder) can cause the same serious adverse events? If standard stimulants do not produce the same serious adverse events, the search for possible mechanisms could be narrowed to pharmacologic effects of fenfluramine that standard stimulants do not share. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?